Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

GSK 1,448.39 -23.11 (-1.57%)
price chart
GlaxoSmithKline 'avoided corporation tax bill of �34m'
Drugs giant GlaxoSmithKline avoided up to �34m in UK corporation tax last year through a deal with Luxembourg, according to an investigation by the BBC.
Glaxo to Begin Hostile Offer for Human Genome Sciences
Glaxo's bid is part of a wave of takeover activity in the pharmaceutical industry as drugmakers seek new products. Roche Holding AG made a hostile offer for Illumina Inc. in January, and abandoned it last month.
Glaxo's Stiefel Unit Loses $1.5 Million Verdict on Buybacks
Stiefel Laboratories lost a $1.5 million jury verdict to a former employee who claimed the company bought back his stock at artificially low prices before its acquisition in 2009 by GlaxoSmithKline Plc. Timothy Finnerty won the judgment on May 16 in ...
Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc., its partner on the drug.
Google's Brin Makes Strides in Hunt for Parkinson's Cure
The advances are encouraging Pfizer Inc. and GlaxoSmithKline Plc to pursue a new class of medicines that may become the first to slow the progress of Parkinson's disease in a unique collaboration that Brin is funding.
Gates Foundation Veteran Yamada Retools Drugmaker Takeda
Tadataka “Tachi” Yamada led global health programs for Bill and Melinda Gates, oversaw GlaxoSmithKline Plc's research, was head physician at the University of Michigan and wrote gastroenterology textbooks.
Nude Olympian Joins Andy Murray to Sell Hot Sports Drink: Health
“I don't think the big brands can do elite sports like we can,” Chief Executive Officer Stephen Moon, a former GlaxoSmithKline Plc executive, said in an interview. “They don't have the credibility. You can't unravel our standing with elite athletes ...
MIDAS: You won't suffer in the Royal Bank of Scotland share swap
Small investors do not trust Royal Bank of Scotland as far as they could throw it. At least that is the case if Midas's mailbag is anything to go by.
Billions of dollars in taxes hang in balance at top court
A nearly 20-year battle between global drug giant GlaxoSmithKline Inc. and the Canada Revenue Agency, now being weighed by the Supreme Court of Canada, could end up rewriting the rules that allow multinationals to shift some of their profits out of ...
Savvy Savers are earning 8.4%*, despite continued volatility in the markets
With savings rates still at all-time lows and continued instability in the global stock markets, savers and investors are moving to alternative forms of investment to get the returns they need.